Therapeutische Umschau. Revue therapeutique · 2008
[Coronary heart disease and dyslipdemia - dosing recommendations at beginning and end of treatment].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blessing Erwin
Аннотация
Secondary prevention in patients with coronary heart disease includes treatment with platelet inhibitors, beta-blockers, ACE inhibitors or AT (1)-blockers, and statins. Initiation of therapy generally does not require a slow gradual dose increase. In treatment naive patients with acute coronary syndromes, administration of a loading dose of aspirin and/or clopidogrel is recommended. To reduce flushing, nicotinic acid should be initiated at low stepwise increasing dosages. beta-blocker therapy should not be stopped acutely in coronary heart disease patients. If beta-blocker therapy has to be terminated, blood pressure should be monitored closely and, if necessary controlled with other medication. Termination of statin therapy in the acute phase after strokes or acute coronary syndromes is associated with increased cardiovascular events and should therefore be avoided.
Предметные рубрики MeSH
Adrenergic beta-AntagonistsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAnticholesteremic AgentsCardiovascular AgentsCombined Modality TherapyCoronary DiseaseDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaPlatelet Aggregation InhibitorsSubstance Withdrawal Syndrome